Upload
enforme
View
2.244
Download
0
Embed Size (px)
DESCRIPTION
Citation preview
Cryoballoon Ablation of PulmonaryVeins for Paroxysmal Atrial FibrillationFirst Results of the North American Arctic
Front STOP-AF Pivotal Trial
Cryoballoon Ablation of PulmonaryVeins for Paroxysmal Atrial FibrillationFirst Results of the North American Arctic
Front STOP-AF Pivotal Trial
Douglas L. Packer, James M. Irwin,Jean Champagne, Peter G. Guerra, Marc Dubuc, Kevin R.
Wheelan, Robert C. Kowal, Vivek Reddy, John W. Lehmann, Richard G. Holcomb, Jeremy N. Ruskin for the STOP-AF
Cryoablation Investigators
ACC Atlanta March 15, 2010
Disclosure InformationDisclosure Information
Dr. D. Packer in the past 12 months has provided consulting services for Biosense Webster, Inc., Biotronik, Inc., Boston Scientific, CyberHeart, InnerPulse, Medtronic, Inc., nContact, Sanofi-Aventis, St. Jude Medical, and Toray Industries. Dr. Packer received no personal compensation for these consulting activities;
Dr. Packer receives research funding from the NIH, Medtronic, Inc., Siemens AG, EP Limited, Minnesota Partnership for Biotechnology and Medical Genomics/ University of Minnesota, Biosense Webster, Inc. and Boston Scientific.
Additional information available from Mayo Communications
Cryoballoon AblationCryoballoon AblationSTOP-AF TrialSTOP-AF Trial
Cryoballoon AblationCryoballoon AblationSTOP-AF TrialSTOP-AF Trial
Trial Design - Multicenter Randomized ClinicalTrial Design - Multicenter Randomized Clinical
PatientsPatients
EnrollmentEnrollment
Enrolling centers Enrolling centers
Follow-upFollow-up
OrganizationOrganization
Principal InvestigatorPrincipal Investigator
Steering Committee ChairSteering Committee Chair
Clinical Events CommitteeClinical Events Committee
Image Core LaboratoryImage Core Laboratory
ECG Core LaboratoryECG Core Laboratory
CROCRO
Study SponsorStudy Sponsor
245 (82 DRUG, 163 CRYO)245 (82 DRUG, 163 CRYO)
Oct 10, 2006-June 30, 2008Oct 10, 2006-June 30, 2008
26 (U.S. and Canada)26 (U.S. and Canada)
12 months12 months
Douglas Packer, MDDouglas Packer, MD
Jeremy Ruskin, MDJeremy Ruskin, MD
Denis Roy, MD, Andrew Epstein, MD, Denis Roy, MD, Andrew Epstein, MD, and Alfred Buxton, MDand Alfred Buxton, MD
eImageeImage
Agility ResearchAgility Research
Cato ResearchCato Research
Medtronic Cryocath LPMedtronic Cryocath LP
STOP-AF Study HypothesesSTOP-AF Study Hypotheses
Primary Effectiveness Hypothesis:Primary Effectiveness Hypothesis:
Cryoballoon ablation would have significantly Cryoballoon ablation would have significantly greater Treatment Success at 12 months than greater Treatment Success at 12 months than Drug therapyDrug therapy
Co-Primary Safety HypothesesCo-Primary Safety HypothesesCryoablation Major AF Event (MAFE) rate would be Cryoablation Major AF Event (MAFE) rate would be
non-inferior to DRUG, andnon-inferior to DRUG, andCryoablation Procedure Event (CPE) rate would be Cryoablation Procedure Event (CPE) rate would be
< 14.8%< 14.8%
BlankingBlankingperiod (90 day)period (90 day)Redo ablationRedo ablation
n=31n=31
Drug Drug optimizationoptimization
90 days90 days
Study Design of the STOP-AF TrialStudy Design of the STOP-AF Trial
AA RxAA Rxfailurefailuren=304n=304
RandomizedRandomized2:1 to ablation vs.2:1 to ablation vs.
Drug RxDrug Rx
ScreeningScreeningExclusionExclusion
n=46n=46
Consent withdrawal Consent withdrawal n=7n=7
Screening failureScreening failuren=6n=6
CryoballoonCryoballoonablationablationn=163n=163
Drug RxDrug Rxn=82n=82
Cross-overCross-overn=65n=65
Follow-Follow-upup
1,3,6,9, 1,3,6,9,
&12 mo&12 mo
HoltersHolters
WeeklyWeekly
TTMsTTMs
Inclusions:Patients >2 AF episodes in 2 months w ECG doc. of 1Rx Failure of > 1 AA Rx
1º Study Outcome Measures1º Study Outcome Measures• Effectiveness: freedom from CTF =Effectiveness: freedom from CTF =
No detectable AF (non-blanked period)No detectable AF (non-blanked period)
No use of nonstudy drugsNo use of nonstudy drugs
No AF interventionsNo AF interventions
• SafetySafety
MAFE:MAFE: composite of disease / treatment composite of disease / treatment SAEsSAEs
CPE (Cryo) only:CPE (Cryo) only: composite of device/procedure-composite of device/procedure-
related SAEsrelated SAEs
Arctic Front CryocatheterArctic Front Cryocatheterand Ablation Methodsand Ablation Methods
Arctic Front CryocatheterArctic Front Cryocatheterand Ablation Methodsand Ablation Methods
Cryoballoon designCryoballoon design
Cryoballoon sizesCryoballoon sizes 23 and 28 mm23 and 28 mm
StructureStructure Double balloonDouble balloon
Cooling (in balloon)Cooling (in balloon) Liquid Liquid gas gastransitiontransition
Balloon deliveryBalloon delivery
CatheterCatheter SteerableSteerable
SheathSheath 14 French14 Frenchdeflectabledeflectable
Ablation Ablation PVI w / no linesPVI w / no lines
Focal CatheterFocal Catheter 99 Fr, 8mm tipFr, 8mm tip
Baseline CharacteristicsBaseline Characteristics
* p value for comparison between DRUG and CRYO subjects* p value for comparison between DRUG and CRYO subjects
Baseline/demographicBaseline/demographic ALLALL DRUGDRUG CRYOCRYO p value*p value*
Age (years)Age (years) 56.656.6 56.456.4 56.756.7 0.800.80
Male (%)Male (%) 77%77% 78%78% 76%76% 0.870.87
Left atrial AP diameter (mm)Left atrial AP diameter (mm) 40.540.5 40.940.9 40.340.3 0.350.35
LV ejection fraction (%)LV ejection fraction (%) 60%60% 61%61% 60%60% 0.410.41
NYHANYHA
None / Class I (%)None / Class I (%) 94%94% 94%94% 93%93% 1.001.00
Class II (%)Class II (%) 6.5%6.5% 6.1% 6.1% 6.7% 6.7% 1.001.00
AF episodes within 2 mo (no.)AF episodes within 2 mo (no.) 23.223.2 21.221.2 24.324.3 0.540.54
Previous cardioversion (%)Previous cardioversion (%) 22%22% 21%21% 23%23% 0.870.87
History of atrial flutter (%)History of atrial flutter (%) 45%45% 44%44% 46%46% 0.790.79
Efficacy-failed AF drugsEfficacy-failed AF drugs
Flecainide (%)Flecainide (%) 36%36% 35%35% 37%37% 0.870.87
Propafenone (%)Propafenone (%) 47%47% 44%44% 49%49% 0.500.50
Sotalol (%)Sotalol (%) 29%29% 31%31% 29%29% 0.880.88
CHADS2CHADS2 0.6 0.6 0.6 0.6 0.6 0.6 0.920.92
Overall SF-36 (v2) scoreOverall SF-36 (v2) score 70.670.6 70.470.4 70.870.8 0.870.87
Baseline Subject-Reported ArrhythmiaBaseline Subject-Reported ArrhythmiaSymptom Prevalence in STOP-AFSymptom Prevalence in STOP-AF
Baseline Subject-Reported ArrhythmiaBaseline Subject-Reported ArrhythmiaSymptom Prevalence in STOP-AFSymptom Prevalence in STOP-AF
0
20
40
60
80
100
Prior AFPrior AFhosphosp
DizzinessDizziness
%%
PalpitationsPalpitations RapidRapidheart beatheart beat
DyspneaDyspnea FatigueFatigue SyncopeSyncope
SubjectsSubjects All (n = 245) All (n = 245) DRUG (n = 82) DRUG (n = 82) CRYO (n = 163) CRYO (n = 163)
3636
1121123434
14142222
7878
213213 7373140140
164164 5656108108
141141
5353
8888
1891896666
123123
121266
66
P=0.451P=0.451
P=0.415P=0.415
P=0.552P=0.552
P=0.775P=0.775P=0.132P=0.132
P=0.423P=0.423
P=0.224P=0.224
Subject-reported arrhythmia symptomsSubject-reported arrhythmia symptoms
Cryoballoon Procedural DataCryoballoon Procedural DataCryoballoon Procedural DataCryoballoon Procedural Data• Acute Procedural Success (APS) ≥ 3 PVs isolated at end of Acute Procedural Success (APS) ≥ 3 PVs isolated at end of
first procedure first procedure 98.2% 98.2%
• Balloon-only per-vein APS of all attempted PVs 90.8% Balloon-only per-vein APS of all attempted PVs 90.8%
• Mean durations:Mean durations:• Procedure = Procedure = 371.0 min (200 – 650) 371.0 min (200 – 650)• Cryoablation = Cryoablation = 65.7 min (17 – 180) 65.7 min (17 – 180)• Fluoro = Fluoro = 62.8 min (8 – 229) 62.8 min (8 – 229)
• Deliveries / PV Deliveries / PV 2.9 – 3.4 2.9 – 3.4
• Cryoballoon temperatures Cryoballoon temperatures - 49ºC to - 54ºC - 49ºC to - 54ºC
• Mean duration / delivery Mean duration / delivery 196 – 230 secs196 – 230 secs
• Repeat cryoablation in 31 Ablation patients Repeat cryoablation in 31 Ablation patients
all with ERAF within the 90 day follow-up 19%all with ERAF within the 90 day follow-up 19%
0
20
40
60
80
100
0 100 200 300 400 500
Primary Effectiveness Analysis Treatment Success
Primary Effectiveness Analysis Treatment Success
Tre
atm
ent
succ
ess
Tre
atm
ent
succ
ess
(%)
(%)
DaysDays
P<0.001P<0.001
vs 7.3% (SE 2.9%)vs 7.3% (SE 2.9%)
CRYO 69.9% 114/163 CRYO 69.9% 114/163
BlankedBlanked DRUG Rx 7.3% 6/82DRUG Rx 7.3% 6/82
30 days
KM estimate 68.6% (SE 3.9%)KM estimate 68.6% (SE 3.9%)
Treatment Success By Analysis MethodTreatment Success By Analysis Method
0
20
40
60
80
100
On Rx
DRUGn = 82
%
CRYOn = 163
(19% redo)
p < 0.001
AbsoluteAbsolute 62.6% 62.6%
n = 67.3%
n = 11469.9%
n = 94(57.7%)
NoDrug
n = 2012.3% n = 98
60.1 %
AbsoluteAbsolute 56.8% 56.8%
p < 0.001
9%
65.8%
On-TreatmentAnalysis
CRYOon / offdrug
n = 163
CRYOsingleproc
n = 163
DRUGn = 67
CRYOn = 114
Intention to TreatOn / Off
DrugSingle
Ablation
Ongoing Drug Rx in CRYO SubjectsTreatment in STOP-AF at 12 Months
Ongoing Drug Rx in CRYO SubjectsTreatment in STOP-AF at 12 Months
Baseline 12 months
PtPt(%)(%)
Anti-arrhythmic DrugsAnti-arrhythmic Drugs WarfarinWarfarin
100100
8080
6060
4040
2020
00
100%100%
26%26%
Baseline 12 months
95%95%
24%24%
Symptom Reduction (CRYO)Symptom Reduction (CRYO)Symptom Reduction (CRYO)Symptom Reduction (CRYO)
CRYO SUBJECTS Baseline
% (n / 163) Month 12 % (n / 163)
Symptomatic AF episodes 100.0% 19.6%
Dizziness 47.9% 8.6%
Palpitations 85.9% 25.2%
Rapid heart beat 66.3% 16.0%
Dyspnea 54.0% 8.6%
Fatigue 75.5% 12.9%
Syncope 3.7% 0.6%
Complication Rate in STOP-AF TrialComplication Rate in STOP-AF Trial
PtPt(%)(%)
CryoablationCryoablationProcedureProcedure
EventsEvents2020
1515
1010
55
00
8.5%8.5%n=7n=7
Major AFMajor AFEventsEvents
CombinedCombinedCPE andCPE and
MAFEMAFE
AblationAblation
3.1 (6.3)%3.1 (6.3)%n=5n=5
14.8%14.8%
P<0.001P<0.001
AblationAblationn=163n=163
DrugDrugn=82n=82
3.1%3.1%n=5n=5
AblationAblationn=163n=163
DrugDrugn=82n=82
8.5%8.5%n=7n=7
6.1%6.1%n=10n=10
P<0.001P<0.001 P=0.595P=0.595
All Serious Adverse Events: Cryoablation 12.3%; Drug Rx 14.6% p=0.69
Summary of All Adverse Events (Intention-to-Treat)
Summary of All Adverse Events (Intention-to-Treat)
Type of Adverse EventCRYO
(n = 163)DRUG(n = 82)
Stroke 4 2.5% 1 1.2%
TIA 3 1.8% 1 1.2%
Tamponade 1 0.6% 1 1.2%
Myocardial infarction 2 1.2% 0 0.0%
Hemorrhage requiring transfusion 3 1.8% 1 1.2%
New atrial flutter 6 3.7% 13 15.9%
Atrial esophageal fistula 0 0.0% 0 0.0%
Death 1 0.6% 0 0.0%
New or worsened AV fistula 2 1.2% 0 0.0%
Pseudoaneurysm 1 0.6% 1 1.2%
Phrenic nerve palsy 22 13.5% 6 7.3%
Persistent phrenic nerve palsy 4 2.5% 0 0.0%
PV stenosis 5 3.1% 2 2.4%
Pulmonary Vein Area ChangePulmonary Vein Area ChangeP
ulm
on
ary
vein
s (n
o.)
Pu
lmo
nar
y ve
ins
(no
.)
Cryoablated pulmonary veins, change inCryoablated pulmonary veins, change incross sectional area from baselinecross sectional area from baseline
-100%-100% -75%-75% -50%-50% -25%-25% -0%-0% +25%+25% >+100%>+100%
10, 1.1%10, 1.1% 23, 2.5%23, 2.5%
180, 19.4%180, 19.4%
433, 46.7%433, 46.7%
219, 23.6%219, 23.6%
35, 3.8%35, 3.8%
n = 927 cryoablated PVsn = 927 cryoablated PVs10 stenotic PVs in 7 pts10 stenotic PVs in 7 pts >75% area change>75% area change1 cryo abl only in 4 pts1 cryo abl only in 4 pts2 cryo abls in 2 pts2 cryo abls in 2 pts1 RF redo in 1 pt1 RF redo in 1 pt
Phrenic Nerve Paralysis in theSTOP-AF Trial in 228 PatientsPhrenic Nerve Paralysis in theSTOP-AF Trial in 228 Patients
0
20
40
60
80
100
ImmediateImmediatepost-procedurepost-procedure
ResolvedResolvedat 12 moat 12 mo
PersistingPersistingat 12 moat 12 mo
11.2%11.2%n=29n=29
86.2%86.2%n=25n=25
13.8%13.8%n=4n=4
28 patients1 with Sx
Limitations of theSTOP-AF Trial
Limitations of theSTOP-AF Trial
• Early Cross-over to cryoballoon ablation Early Cross-over to cryoballoon ablation from Drug Rx after 14-28 daysfrom Drug Rx after 14-28 days
• Shorter concurrent drug treatment periodShorter concurrent drug treatment period
• Permitted redo ablations during blankingPermitted redo ablations during blanking
• Use of PV area vs diameter for PV Use of PV area vs diameter for PV stenosis Dxstenosis Dx
• Limited choice of antiarrhythmic drugsLimited choice of antiarrhythmic drugs
ConclusionsConclusions
• Cryoballoon ablation is effective for treating Cryoballoon ablation is effective for treating recurrent drug-refractory paroxysmal AF in recurrent drug-refractory paroxysmal AF in symptomatic patientssymptomatic patients
• Balloon-only ablation is feasible in the majority of Balloon-only ablation is feasible in the majority of patientspatients
• Pulmonary vein stenosis may occur with Pulmonary vein stenosis may occur with cryoablationcryoablation
• Phrenic nerve injury occurring with cryoablation is Phrenic nerve injury occurring with cryoablation is largely reversiblelargely reversible
• The STOP-AF Trial endpoints were all reachedThe STOP-AF Trial endpoints were all reached